Afinitor significantly reduces seizures in Phase III TSC study
Results from a Phase III study show Novartis’ Afinitor (everolimus), when used as an adjunctive therapy, significantly reduced treatment-resistant seizures associated with tuberous sclerosis complex (TSC) compared to placebo.
Click on this link for more information.
